Atuveciclib Racemate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206702

CAS#: 1414943-88-6 (racemic)

Description: Atuveciclib, also known as BAY1143572, is a highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I. BAY1143572 inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. BAY 1143572 had potent and highly selective PTEFb-kinase inhibitory activity in the low nanomolar range against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY 1143572 also showed single agent in vivo efficacy at tolerated doses in various xenograft tumor models in mice and rats upon once daily oral administration.

Chemical Structure

img
Atuveciclib Racemate
CAS# 1414943-88-6 (racemic)
Instruction

Theoretical Analysis

MedKoo Cat#: 206702
Name: Atuveciclib Racemate
CAS#: 1414943-88-6 (racemic)
Chemical Formula: C18H18FN5O2S
Exact Mass: 387.12
Molecular Weight: 387.433
Elemental Analysis: C, 55.80; H, 4.68; F, 4.90; N, 18.08; O, 8.26; S, 8.27

Price and Availability

Size Price Availability Quantity
5mg USD 350 2 Weeks
10mg USD 550 2 Weeks
Bulk inquiry

Related CAS #: 1414943-88-6 (racemic)   1414943-94-4    

Synonym: BAY1143572; BAY 1143572; BAY-1143572. Atuveciclib

IUPAC/Chemical Name: (3-((4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino)benzyl)(imino)(methyl)-l6-sulfanone

InChi Key: ACWKGTGIJRCOOM-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H18FN5O2S/c1-26-16-9-13(19)6-7-15(16)17-21-11-22-18(24-17)23-14-5-3-4-12(8-14)10-27(2,20)25/h3-9,11,20H,10H2,1-2H3,(H,21,22,23,24)

SMILES Code: O=S(C)(CC1=CC=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=C1)=N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 387.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ruff JP, Kretz AL, Kornmann M, Henne-Bruns D, Lemke J, Traub B. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death. Anticancer Res. 2021 Dec;41(12):5973-5985. doi: 10.21873/anticanres.15416. PMID: 34848451.


2: Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K, Denner K, Bömer U, Schäfer M, Eis K, Valencia R, Ince S, von Nussbaum F, Mumberg D, Ziegelbauer K, Klebl B, Choidas A, Nussbaumer P, Baumann M, Schultz-Fademrecht C, Rühter G, Eickhoff J, Brands M. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793. doi: 10.1002/cmdc.201700447. Epub 2017 Oct 16. PMID: 28961375; PMCID: PMC5698704.


3: Ni W, Zhang F, Zheng L, Wang L, Liang Y, Ding Y, Yik JHN, Haudenschild DR, Fan S, Hu Z. Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway. Front Cell Dev Biol. 2020 Sep 10;8:579658. doi: 10.3389/fcell.2020.579658. PMID: 33015073; PMCID: PMC7511812.


4: Brisard D, Eckerdt F, Marsh LA, Blyth GT, Jain S, Cristofanilli M, Horiuchi D, Platanias LC. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018 Dec 18;9(99):37305-37318. doi: 10.18632/oncotarget.26468. PMID: 30647871; PMCID: PMC6324664.


5: Johansson P, Dierichs L, Klein-Hitpass L, Bergmann AK, Möllmann M, Menninger S, Habenberger P, Klebl B, Siveke JT, Dührsen U, Choidas A, Dürig J. Anti- leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. Ther Adv Hematol. 2020 Oct 13;11:2040620720933761. doi: 10.1177/2040620720933761. PMID: 33117517; PMCID: PMC7570784.


6: Schonhofer C, Yi J, Sciorillo A, Andrae-Marobela K, Cochrane A, Harris M, Brumme ZL, Brockman MA, Mounzer K, Hart C, Gyampoh K, Yuan Z, Montaner LJ, Tietjen I. Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. Biochem Pharmacol. 2021 Apr;186:114462. doi: 10.1016/j.bcp.2021.114462. Epub 2021 Feb 10. PMID: 33577894; PMCID: PMC8052299.


7: Lyle L, Daver N. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. Am J Manag Care. 2018 Aug;24(16 Suppl):S356-S365. PMID: 30132679.


8: Han Y, Xing K, Zhang J, Tong T, Shi Y, Cao H, Yu H, Zhang Y, Liu D, Zhao L. Application of sulfoximines in medicinal chemistry from 2013 to 2020. Eur J Med Chem. 2021 Jan 1;209:112885. doi: 10.1016/j.ejmech.2020.112885. Epub 2020 Sep 28. PMID: 33227576.


9: Štětková M, Growková K, Fojtík P, Valčíková B, Palušová V, Verlande A, Jorda R, Kryštof V, Hejret V, Alexiou P, Rotrekl V, Uldrijan S. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells. Cell Death Dis. 2020 Sep 15;11(9):754. doi: 10.1038/s41419-020-02971-3. PMID: 32934219; PMCID: PMC7494941.


10: Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. J Med Chem. 2021 Aug 12;64(15):11651-11674. doi: 10.1021/acs.jmedchem.1c01000. Epub 2021 Jul 15. PMID: 34264057.


11: Dahl NA, Danis E, Balakrishnan I, Wang D, Pierce A, Walker FM, Gilani A, Serkova NJ, Madhavan K, Fosmire S, Green AL, Foreman NK, Venkataraman S, Vibhakar R. Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma. Cell Rep. 2020 Apr 7;31(1):107485. doi: 10.1016/j.celrep.2020.03.049. PMID: 32268092.


12: Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S. Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma. Haematologica. 2018 Dec;103(12):2059-2068. doi: 10.3324/haematol.2018.191395. Epub 2018 Aug 3. PMID: 30076184; PMCID: PMC6269314.